Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qingdao NovelBeam Technology CoSHSE:688677 +3.79%92 Cyclically Adjusted PS Ratio is 22.60 as of Aug. 16, 2026, which is 52% above its 10-year median of 14.90. GuruFocus rates SHSE:688677 with a GF Score™ of 92/100 and a GF Value™ of ¥63.65 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 523 Medical Devices & Instruments companies, Qingdao NovelBeam Technology Co ranks worse than 97.13% on this metric.
The historical rank and industry rank for Qingdao NovelBeam Technology Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
SHSE:688677'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 11.72 Med: 14.9 Max: 32.88
Current: 22.62
During the past 13 years, Qingdao NovelBeam Technology Co's highest Cyclically Adjusted PS Ratio was 32.88. The lowest was 11.72. And the median was 14.90.
SHSE:688677's Cyclically Adjusted PS Ratio is ranked worse than 97.13% of 523
companies
in the Medical Devices & Instruments industry
Industry Median: 2.34
vs SHSE:688677: 22.62
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Qingdao NovelBeam Technology Co's adjusted revenue per share data of for the fiscal year that ended in Dec25 was ¥5.082. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ¥3.31 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Qingdao NovelBeam Technology Co (SHSE:688677) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Qingdao NovelBeam Technology Co Cyclically Adjusted PS Ratio Related Terms
Qingdao NovelBeam Technology Co Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qingdao NovelBeam Technology Co Cyclically Adjusted PS Ratio Chart
SHSE:688677 vs ISRG, BDX, MDLN: Cyclically Adjusted PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, Qingdao NovelBeam Technology Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qingdao NovelBeam Technology Co Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qingdao NovelBeam Technology Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Qingdao NovelBeam Technology Co's Cyclically Adjusted PS Ratio falls into.
Qingdao NovelBeam Technology Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 22.60 mean?
Qingdao NovelBeam Technology Co (SHSE:688677) has a Cyclically Adjusted PS Ratio of 22.60 as of Aug. 16, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Qingdao NovelBeam Technology Co and its competitors. This is 52% above median its historical median of 14.90. Over the past decade, Qingdao NovelBeam Technology Co's Cyclically Adjusted PS Ratio has ranged from 11.72 to 32.88. According to the industry distribution chart, Qingdao NovelBeam Technology Co ranks #508 out of 523 companies in the Medical Devices & Instruments industry, placing it in the top 97.1%.
Is Qingdao NovelBeam Technology Co's Cyclically Adjusted PS Ratio too high?
Qingdao NovelBeam Technology Co's current Cyclically Adjusted PS Ratio of 22.60 is 52% above median its 10-year median of 14.90. Over the past 10 years, this metric has ranged from a low of 11.72 to a high of 32.88. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.34. Qingdao NovelBeam Technology Co's value of 22.60 is 865.8% above this industry median. Based on the distribution chart, Qingdao NovelBeam Technology Co ranks #508 out of 523 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Qingdao NovelBeam Technology Co has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qingdao NovelBeam Technology Co's Cyclically Adjusted PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Qingdao NovelBeam Technology Co ranks #508 out of 523 companies for Cyclically Adjusted PS Ratio. This places Qingdao NovelBeam Technology Co in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.34. Qingdao NovelBeam Technology Co's value of 22.60 is 865.8% above this benchmark. Historically, Qingdao NovelBeam Technology Co's own Cyclically Adjusted PS Ratio has ranged from 11.72 to 32.88 over the past decade. While the company's 10-year median is 14.90 vs. the industry median of 2.34, Qingdao NovelBeam Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.34, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qingdao NovelBeam Technology Co's current Cyclically Adjusted PS Ratio of 22.60 is 865.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Qingdao NovelBeam Technology Co and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qingdao NovelBeam Technology Co's current Cyclically Adjusted PS Ratio is 22.60, which is 52% above median its own 10-year median of 14.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qingdao NovelBeam Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Qingdao NovelBeam Technology Co (SHSE:688677) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥63.65, compared to a current price of ¥74.80 — trading 17.5% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 22.60, which is 52% above median its 10-year median of 14.90 and 865.8% above the Medical Devices & Instruments industry median of 2.34. Qingdao NovelBeam Technology Co's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Qingdao NovelBeam Technology Co (SHSE:688677), the current Cyclically Adjusted PS Ratio is 22.60 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qingdao NovelBeam Technology Co (SHSE:688677) Overvalued in 2026?
Based on GuruFocus' analysis, Qingdao NovelBeam Technology Co stock appears to be overvalued.
The current stock price of ¥74.80 is trading 17.5% above its estimated GF Value™ of ¥63.65.
GuruFocus considers Qingdao NovelBeam Technology Co to be Modestly Overvalued.
Key valuation signals for SHSE:688677:
Cyclically Adjusted PS Ratio: 22.60 (52% above median its 10-year median of 14.90)
GF Value™: ¥63.65 vs. price of ¥74.80 (17.5% above fair value)
Industry Position: 865.8% above the Medical Devices & Instruments median (#508 of 523)
No single metric tells the full story. See the SHSE:688677 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qingdao NovelBeam Technology Co Ltd is engaged in the research and development, production and sales of medical endoscope equipment and optical products. The product portfolio of the group includes Endoscope, Camera coupler, Camera lens, Medical optics, Biometrics and others.
92GF Score
Get the complete analysis for SHSE:688677
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688677 has been successfully added to your 
